Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Phase II Trial to Evaluate the Safety of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa

NCT03001622 is registered in ClinicalTrials.gov with InflaRx GmbH as lead sponsor.

NCT NCT03001622
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03001622 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Phase II Trial to Evaluate the Safety of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa
Lead sponsor
InflaRx GmbH
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2016
Completion date
July 31, 2017
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis suppurativa